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Abstract: Eosinophils are well known to contribute significantly to Th2 immunity, such as allergic
inflammations. Although basophils have often not been considered in the pathogenicity of allergic
dermatitis and asthma, their role in Th2 immunity has become apparent in recent years. Eosinophils
and basophils are present at sites of allergic inflammations. It is therefore reasonable to speculate that
these two types of granulocytes interact in vivo. In various experimental allergy models, basophils
and eosinophils appear to be closely linked by directly or indirectly influencing each other since
they are responsive to similar cytokines and chemokines. Indeed, basophils are shown to be the
gatekeepers that are capable of regulating eosinophil entry into inflammatory tissue sites through
activation-induced interactions with endothelium. However, the direct evidence that eosinophils
and basophils interact is still rarely described. Nevertheless, new findings on the regulation and
function of eosinophils and basophils biology reported in the last 25 years have shed some light
on their potential interaction. This review will focus on the current knowledge that basophils may
regulate the biology of eosinophil in atopic dermatitis and allergic asthma.
Keywords: basophils; eosinophils; chemotaxis; eosinophil-basophil interaction; allergic inflamma-
tion; eosinophil infiltration; atopic dermatitis; allergic asthma
1. Eosinophils and Basophils Are Pivotal Players in the Progression of
Allergic Inflammation
Type 2 immunity in the lung and skin is complex involving different types of cells, cells
of adaptive and innate immunity, and a multi-layered network of cytokines, chemokines, and
effector mediators [1]. Several studies demonstrate that basophils and eosinophils are essential
contributors in the initiation, progression, and maintenance of allergic inflammations.
Basophils are the least abundant circulating granulocytes representing 0.5–1% of
all leukocytes. They resemble mast cells in several characteristic features, especially in
the expression of the high-affinity immunoglobulin E (IgE) receptor FcεRI on their cell
surface, which directly binds to the IgE. The cross-linking of FcεRI and IgE complexes
upon allergen challenge leads to the release of immunoregulatory and effector mediators,
including Th2 cytokines like interleukin-4 (IL-4) and IL-13, histamine, and leukotriene
(LTC4) [2]. Due to their resemblance to mast cells and scarcity, basophils have often been
considered insignificant and analyzed only as a surrogate of the tissue-dwelling mast
cells. However, recent studies revealed the unique functions of basophils in chronic al-
lergic diseases such as allergic rhinitis and asthma [3]. Infiltration of basophils and not
mast cells during late-phase allergic reaction in the lungs is pivotal for the severity of
the inflammatory response as evidenced by the observation that most histamine positive
cells are basophils and the simultaneous absence of mediators like tryptase exclusively
secreted by mast cells [4]. Histamine and pro-inflammatory lipid mediators (like LTC4)
released by activated basophils increase vascular permeability and mucus production and
promote contraction of smooth muscle cells surrounding the bronchi thereby promoting
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bronchoconstriction [2]. A non-redundant function of basophils in the context of allergic
inflammation is the rapid secretion of IL-4 and IL-13 at levels greater than any other cells
capable of secreting these cytokines, including Th2 cells, mast cells, and eosinophils [5].
The release of IL-13 stimulates goblet cells to produce more mucus and to proliferate [6].
In synergy with IL-13, IL-4 provides additional signals for isotype switching to IgE in
B cells [5]. Moreover, it has been shown that IL-4 and IL-13 trigger CCL11 release and
vascular cell adhesion molecule-1 (VCAM-1) expression from endothelial cells resulting in
infiltration of eosinophils [2]. By producing IL-4 and IL-13, basophils regulate infiltration
of eosinophils [7], which is confirmed in a recent study using basophil-deficient mice [8].
Furthermore, basophils also secrete various chemoattractants, including IL-8 (own obser-
vation [9]) and CCL5 (RANTES) [7], which promote the influx of potent inflammatory
cells, neutrophils, eosinophils, and macrophages. Several lines of evidence from murine
models suggest basophils’ direct role in antigen presentation for Th2 responses through
MHC-II expression [10–12], initiation, and maintenance of IgE-mediated Th2 responses
possibly independent of T cells and mast cells (reviewed in [13]). Despite this evidence
from mouse models of the multifaceted roles of basophils in Th2 allergic inflammation,
the crucial function of basophils in human allergic diseases remains undefined because of
inadequate supporting evidence.
In addition to the infiltration of basophils, migration of eosinophils to inflammation
sites is another essential characteristic of allergic inflammation. Eosinophils are also
relatively rare (about 1–5% of all leukocytes) circulating granulocytes. The content of
eosinophil granules differs from that of basophils. It mainly comprises cationic proteins
such as major basic protein (MPB), eosinophil cationic protein (ECP), eosinophil peroxidase,
and eosinophil-derived neurotoxin [2]. However, some of the compounds secreted by
eosinophils are also found in basophils, such as IL-4 and IL-13 [2]. In the context of allergic
inflammation, the release of cationic mediators has been shown to cause injury to epithelial
tissue damage and thereby contribute to airway hyperresponsiveness [14]. MBP released
by eosinophils may cause a positive feedback loop since it provokes histamine release and
LTC4 from basophils [15].
Basophils and eosinophils are present at sites of allergic inflammation in the airways
and skin [4,16–21]. Namely, increased numbers of basophils are reported in the lung tissues
of fatal asthmatics [16], in sputum and bronchoalveolar lavage (BAL) fluid from asthmat-
ics after allergen challenge [4,20]. Interestingly, upon allergen challenge, the increase in
basophil percentages in BAL fluids negatively correlate with basophil percentages in the
blood, indicating the recruitment of basophils from the circulation into the lung [20]. The
presence of basophil infiltrates in atopic allergic inflammation in human skin was estab-
lished using basophil granule-specific monoclonal antibody (mAb) [18]. In an extension
of this observation, Ying and co-workers demonstrated, besides basophils, eosinophils
infiltrate 6 h after allergen challenge in late-phase reaction [22]. Consistently, concomitant
recruitment of basophils and eosinophils is reported in the skin lesions of eosinophilic
pustular folliculitis and atopic dermatitis [21,23]. In asthma, elevated levels of eosinophil
count and their mediator, MBP in BAL fluid from asthmatics are also reported [24]. A
comparative study between basophils and eosinophils in atopic asthmatics identifies their
presence in bronchial biopsies, and their numbers are further enhanced after allergen
challenge in the late-phase of asthmatic and skin reactions [17]. Similarly, an increase
in numbers of both airway basophils and eosinophils in atopic asthmatics’ sputum after
allergen inhalation challenge is observed [19]. Interestingly, it has been demonstrated that
eosinophil-derived MBP directly activates the release of histamine and LTC4 from human
basophils [15,25]. Consistent with this observation, in several experimental allergy models,
basophils and eosinophils appear to be closely linked by directly influencing each other or
indirectly due to being responsive to similar cytokines and chemokines [7,8,26]. Therefore,
it is reasonable that basophils and eosinophils interact with each other at sites of allergic
inflammation. In 1995, Thomas et al. reviewed the potential functional network between
basophils and eosinophils [27]. New findings in recent years give some more insights into
Cells 2021, 10, 895 3 of 18
the mechanisms of interaction between these two types of granulocytes. Eosinophils are
increased in allergic inflammation and are often considered the main actors of the late
phase of allergic rashes. However, although present at low numbers, basophils seem to
be pivotal for allergic inflammation progression and maintenance. We will summarize
whether and how basophils can regulate the function of eosinophils in allergic dermatitis
and asthma.
2. Chemotaxis
There are several potential mechanisms on how cells of different types may regulate
each other. One of them is undoubtedly the attraction of a particular cell type from
circulation to a specific tissue guided by an increasing gradient of chemoattractants. This
type of cell migration is known as chemotaxis. It is well established that tissue-residing
mast cells play an essential role in triggering infiltration of eosinophils and basophils to
sites of inflammation (reviewed in [28]). Moreover, IL-5, produced by allergen-specific
T-cells, is considered a key molecule of eosinophil chemotaxis [29,30], whereby systemically
delivered IL-5 seems to be superior to IL-5 expressed locally in the airways on impacting
airway eosinophilia [31]. Whether basophils and eosinophils attract each other to sites of
inflammation such as irradiated skin lesions or inflamed airways is less well documented.
Nevertheless, studies using basophil and eosinophil-depleted mice shed some light on this
topic and will be summarized in the next section (Tables 1 and 2).
Table 1. Mouse models of allergic skin diseases.






CD49bpos cell fraction Yes [32]
Anti-CD200R3 (B103) Yes [33]
Mcpt8Cre BAC Yes [34]
BasoDTR mice Yes [35]
ICD i.p NAC NAC and croton oil
on skin
Anti-FcεRIα (MAR-1) Yes [36]
BasTRECK Yes [36]
IgE-CAI, IgE-chronic allergic inflammation; OVA, ovalbumin; ICD, irritant contact dermatitis; NAC, N-Acetylcystein.
Table 2. Mouse models of allergic airway inflammation.




i.p. OVA-alum i.t. OVA Anti-FcεRIα (MAR-1) No [37]
i.p. OVA-alum i.n. OVA
Mcpt8Cre BAC No [34]
Anti-FcεRIα (MAR-1) Yes [38]
Anti-CD200R3 (B103) Yes [38]
HDM-induced asthma
i.n. HDM i.n. HDM Anti-FcεRIα (MAR-1) Yes [39]
i.n. HDM i.n. HDM Anti-CD200R3 (B103) Yes [39]
OVA, Ovalbumin; HDM, house dust mite.
2.1. Contribution of Basophils to Regulate Eosinophil Infiltration to Inflamed Skin
By subcutaneous injection of TNP-conjugated ovalbumin into anti-TNP IgE transgenic
mice [40], Mukai and co-workers were able to induce an immediate as well as a late and
chronic phase of IgE-mediated chronic allergic dermatitis (IgE-CAI) as evident by infiltra-
tion of granulocytes and ear swelling 2–4 days after injection. Interestingly, the induction
and progression of early, late, and chronic allergic inflammation was not dependent on T
cells, NK-T cells, and NK cells. In contrast, mast cells impacted granulocyte infiltration
during the immediate and late but not the chronic phase of allergic skin inflammation [32].
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Basophil-depleted mouse models did not exist at that time point. However, some indirect
evidence that basophils are regulators of eosinophil infiltration during the chronic phase of
allergic inflammation was given by the fact that transfer of the DX5 (CD49b) positive cell
fraction, consisting 15–25% of basophils, into FcγR-/- mice restored IgE-CAI [32].
More direct evidence that basophils regulate eosinophil infiltration and disease pro-
gression in IgE-CAI is given in a murine model in which basophils were depleted by the
usage of the basophil specific anti-CD200R3 antibody (Ba103). Depletion of basophils
inhibited the infiltration of eosinophils and the development and maintenance of IgE-CAI.
In contrast, in passive cutaneous anaphylaxis, mediated mainly by mast cells, and contact
hypersensitivity, a model for type IV hypersensitivity, the clinical symptoms and eosinophil
infiltration were not affected by basophil depletion [33]. These findings are in line with
studies performed in constitutively basophil-depleted Mcpt8Cre BAC transgenic mice [34].
Expressing the human diphtheria toxin (DT) receptor under CD203 or the eosinophil
peroxidase promotor, basophil, and eosinophil depletion, respectively, was obtained upon
administration of DT [35]. IgE-CIA was abolished in basophil-depleted BasoDTR mice,
confirming the essential role of basophils to control eosinophil infiltration. Besides, Th2
cytokines (IL-4, IL-13, IL-6) and Th1 cytokines (IFNγ and IL-12) were reduced. Notably,
CCL24 (eotaxin-2) expression, known to regulate eosinophils’ infiltration, was significantly
decreased in BasoDTR mice. In eosinophil-ablated EoDTR mice, IgE-CIA was diminished
as well. Unfortunately, whether the attraction of basophils to inflamed skin was affected in
the EoDTR mice was not addressed. Nevertheless, although the cytokines as mentioned
above were expressed to a lesser degree in EoDTR mice compared to wild-type mice,
EoDTR mice showed higher amounts of these cytokines than BasoDTR mice suggesting
that basophils initiate and eosinophils ameliorate IgE-CIA [35].
In line with the IgE-CAI mouse models are reported data of croton oil-induced irritant
contact dermatitis (ICD). Basophils infiltrated lesion skin within 3 h, followed by eosinophil
migration at 24 h upon induction of ICD, suggesting that basophils have the capacity to
imprint attraction of eosinophils by the simple fact that basophil infiltration occurs earlier
than the one of eosinophil. Further analysis in anti-FcεRIα antibody (MAR-1)-treated and
basophil-depleted Bas TRECK mice confirmed a significant reduction of eosinophils in
basophil-depleted mice [7].
Therefore, these mouse studies point to basophils’ vital role in regulating eosinophil
infiltration to irradiated skin lesions during chronic allergic dermatitis. However, in con-
trast to these mouse models, in atopic asthma patients in whom late-phase skin reaction
was induced, eosinophil infiltration to inflamed skin occurred prior to basophil infiltration,
whereby maximal numbers of eosinophils were already observed at 6 h followed by ba-
sophils infiltration at 24 h [17,22]. In skin lesions of atopic dermatitis, the accumulation
of both basophils and eosinophils are reported [21,36]. It has been widely reported that
eosinophil recruitment is associated with increased expression of adhesion molecules, in-
cluding VCAM-1 [41,42] and specific chemotactic factors such as CCL11 [43]. Interestingly,
in basophil-depleted mice, eosinophil infiltration was found abrogated, and furthermore,
the basophil-specific deletion of IL-4 showed diminished VCAM-1 up-regulation on en-
dothelial cells [8]. Consistently, the accumulation of basophils that express IL-4 in skin
lesions of atopic dermatitis patients was observed [36]. Taken together, it is plausible
that infiltrated basophil represent a source of IL-4 that aids in eosinophil recruitment in
atopic dermatitis. However, further investigations are necessary to better understand the
functional significance of skin-infiltrating basophils in human atopic dermatitis.
2.2. The Controversial Role of Basophils in Affecting Eosinophil Infiltration to Sites of
Inflammation in the Airways
Findings in mouse models of allergic airway inflammation are less consistent than
the ones of IgE-CAI and chronic contact dermatitis. For instance, a mouse study of OVA-
induced late asthmatic response revealed that basophil infiltration to sites of allergic
airway inflammation and the release of IL-4, IL-5, and IL-13 into BAL fluids occurs before
eosinophil, T cell, and monocyte infiltration [37]. However, although depletion of basophils
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and mast cells by anti-FcεRIαMAR-1 antibody reduced the early phase of specific airway
resistance (sRAW), the late phase of sRAW and late eosinophil infiltration to lung tissue
was not affected [44]. Consistently, using the basophil-depleted Mcpt8Cre BAC transgenic
mice, Ohnmacht and their research team demonstrated that the infiltration of eosinophils
was not abrogated upon OVA challenge [34]. In contrast, MAR-1 and Ba103 treatment
resulted in a significant reduction of eosinophil number in BAL fluid and airways, and
reduced IL-4 expression in lung tissue in the study conducted by Zhong et al. [38]. Besides,
whether basophils have the capacity to contribute to eosinophil infiltration seems to not
only depend on the approach of basophil depletion, but also on the allergen used to
induce airway inflammation. For instance, Hammad and co-workers compared the effects
of the MAR-1 and Ba103 antibody, respectively, on the infiltration of eosinophils and
Th2 cytokine secretion in BAL fluids in an allergic airway inflammation models using
house dust mite (HDM) [39]. They found that MAR-1 antibody administration, which
recognizes FcεRIα expressed on basophils, dendritic cells, and mast cells, resulted in a
significant reduction of eosinophil infiltration and Th2 cytokine production. In contrast,
treatment with the basophil specific anti-CD200R3 antibody Ba103 did not significantly
affect Th2 cytokine release in BAL fluids. Furthermore, it resulted in a less pronounced but
still significant reduction of eosinophil infiltration compared to MAR-1 treated mice [39].
Whether eosinophil depletion affects infiltration of basophils has not been studied in
detail. However, interestingly enough, in an HDM-asthma model, it has been shown
that eosinophil depletion by the usage of anti-CCR3 antibodies resulted in an 80 to 85%
reduction of eosinophils in BAL and lung but did not affect numbers of Th2 cells and airway
remodeling. These findings were confirmed in ∆dblGATA eosinophil-ablated mice [45].
In general, basophils’ role in regulating eosinophils’ trafficking seems different in
allergic skin and airway inflammation. The reasons for this are manifold and certainly
include the fact that allergic asthma and atopic dermatitis are two separate diseases with
different underlying mechanisms. In addition, conflicting results can be explained by the
undeniable fact that mouse models do not always represent human diseases. We refer
the reader to the review of Graham et al. summarizing allergic mouse models and their
contribution to understand the human diseases [46].
2.3. Overview of the General Mechanisms of Eosinophil and Basophil Chemotaxis
The regulation of eosinophils’ chemotaxis has been investigated in many studies.
Before we describe the potential mechanism of how basophils may guide the infiltration of
eosinophils to inflamed skin, we will shortly outline the most general means of chemotactic
regulation of basophils and eosinophils (also summarized in Figure 1).
2.4. The CCR3/CCL11/CCL24 Axis
CCL11 (eotaxin-1), CCL24 (eotaxin-2), CCL26 (eotaxin-3), CCL5 (RANTES), CCL3
(MIP-1α), and CCL7, CCL8, CCL13 (MCP-3, -2 and 4), all recognized by CCR3, are promi-
nent eosinophil-active chemokines. CCR3 is constitutively expressed on eosinophils from
mice [47] and humans [48] and on basophils from humans [49] but not from mice. Murine
models of allergic airway inflammation demonstrated the prominent role of CCR3 in regu-
lating infiltration of eosinophils to inflamed lung tissue. Depending on the immunization
protocol that has been used to induce airway inflammation, numbers of eosinophils in BAL
fluid and lung tissue were modestly [50] or strongly reduced in CCR3-deficient mice [51,52].
It is less well known whether CCR3 regulates infiltration of basophils to inflamed airways
to a similar extent as eosinophils since basophils from mice do not express CCR3. Neverthe-
less, Sénéchal and co-workers demonstrated in a mouse model of human skin xenografts
and autologous transfer of PBMC from allergic donors that basophil infiltration to inflamed
skin was not affected by anti-CCR3 antibody administration prior to allergen challenge [53].
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Figure 1. Orchestration of basophil-mediated eosinophil recruitment during allergic inflammation in humans. Basophils
play a crucial immunoregulatory role in releasing cytokines such as interleukin (IL)-4 and IL-13 at the inflammatory tissue
foci. Basophils-derived IL-4 induces the upregulation of the adhesion molecules like vascular cell adhesion molecule-1
(VCAM-1) on endothelial cells, which facilitates eosinophil infiltration. Basophil-derived IL-4 in synergy with tumor
necrosis factor-alpha (TNF-α) stimulates fibroblasts and endothelial cells to produce eotaxins, including CCL11 and CCL24,
which can, in turn, attract CCR3positive eosinophils. IL-4 activates lung-resident group 2 innate lymphoid cells (ILC2) to
release IL-5, IL-13, and CCL11, stimulating eosinophils’ infiltration. IL-13 stimulates airway macrophages to release CCL24,
which regulates eosinophil migration to the airways. Infiltrated inflammatory cells like macrophages and monocytes in the
airways activate and secrete IL-1β, which in turn induce basophils to release the potent neutrophil chemoattractant, IL-8.
IL-3 secreted by T cells, mast cells, or even basophils themselves induces the expression of CCL5 in basophils, which in turn
regulates the trafficking of eosinophils.
CCL11, CCL24, and CCL26 are high-affinity ligands of CCR3. The levels of plasma
CCL11 are significantly increased in atopic dermatitis patients [54] and during asthma
exacerbation compared to the stable phase of asthma [55]. Moreover, elevated levels of
CCL11 in plasma seem to have functional consequences since they are inversely associated
with predicted FEV1 [56]. In line with this, is the observation that in the airways of asthma
patients compared with healthy controls mRNA of CCL11 and CCL24 are increased at
steady state. However, in contrast to CCL26 mRNA, CCL11 and CCL24 mRNAs are not
further upregulated in the airways upon allergen challenge [57]. The same accounts for
atopic dermatitis patients in whom serum levels of CCL26 correlate with disease severity
while CCL24 does not [58].
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Interestingly, CCL11 and CCL24 might have different importance in health and disease.
On the one hand, CCL11, which, in humans, is constitutively expressed in the small
intestine and colon and to a lesser extent in heart, kidney, and pancreas [59–61], seems to
be more prominent than CCL24 in regulating eosinophil infiltration to the gastrointestinal
tract at baseline in healthy state [62,63]. CCL24, on the other hand, seems to dominate the
regulation of eosinophil infiltration under pathophysiological conditions. For instance,
CCL24 and CCL11/CCL24 double-deficient mice show fewer eosinophils in BAL fluids 20 h
upon OVA-induced experimental airway inflammation, while numbers of eosinophils in
CCL11 knockouts were comparable to wild-type control mice [40]. This might be explained
by the fact that in contrast to CCL11, the expression of CCL24 is prolonged up to 120 h
upon allergen challenge and thus has the capacity to regulate eosinophil infiltration at
later time points. Consistently, targeted gene disruption of CCL11 results in reduced
numbers of eosinophils in BAL fluid after 18 h but not after 48 h OVA-challenge [64].
In terms of basophil chemotaxis, in vitro tests demonstrated that CCL11 and CCL24 are
chemoattractants of human basophils, whereby CCL11 seems to be more potent than CCL24
in attracting basophils [49,65,66]. Eosinophil- and basophil-active chemotaxis of CCL11
and CCL24 and their temporal expression was confirmed in humans upon cutaneous
allergen challenge. However, expression of CCR3, CCL11, and CCL24 did not correlate
with numbers of basophils upon cutaneous allergen challenge questioning whether the
eotaxin-CCR3 axis is essential in regulating infiltration of basophils to inflamed skin in
humans [22].
Besides the eotaxin-family, the other known agonists of CCR3 have been demonstrated
to impact eosinophil and basophil attraction. For instance, increased concentrations of
CCL5 and CCL3 have been detected in BAL fluid of asthma patients compared to healthy
non-smokers [67]. The chemotactic capacity of these ligands has been demonstrated by
in vitro tests using trans-wells in whichBAL fluid was added to one side and purified
eosinophils from asthma patients to the other side. Importantly, the usage of anti-CCL5
and anti-CCL7 antibody demonstrated inhibition of eosinophil chemotaxis [67].
There are several recent reviews summarizing findings on the regulation of eosinophil
and basophil chemotaxis to inflamed skin and lung and the further effects of the corre-
sponding chemokines such as induction of granulocyte degranulation [68,69].
2.5. The GM-CSF Cytokine Family Axis
Members of the GM-CSF cytokine family (IL-3, IL-5, and GM-CSF) tremendously affect
the maturation, development, and biology of eosinophils and basophils. Several studies
investigated the contribution of IL-3, IL-5, and GM-CSF on chemotaxis (reviewed [70]).
For instance, IL-5 and GM-CSF are found elevated in the BAL fluids from allergic subjects
after the antigen challenge [71–73]. Interestingly, it has also been observed that eosinophils
from BAL fluid of antigen challenged-allergic subjects showed enhanced transendothelial
migration, suggesting eosinophils are activated in vivo by IL-5 and GM-CSF [74].
Receptors for all three GM-CSF cytokine family consist of a cytokine specific α-chain
(IL-3Rα, IL-5Rα, or GM-CSFRα) and a common β-chain [75]. Both blood basophils and
eosinophils express receptors for all members of the GM-CSF cytokine family. The sensitiv-
ity and magnitude of cell’s responses elicited by different GM-CSF family members are
different and dependent on the density of surface expression of the corresponding receptor
α-chains on basophils and eosinophils [76]. For instance, IL-3Rα mRNA is abundantly
expressed in basophils, whereas in eosinophils, IL-5Rα mRNA is dominant among all
the α-chains of three GM-CSF cytokine receptors [77]. Consistently, among the three GM-
CSF cytokines, IL-3 potently activates various basophil functions, whereas IL-5 efficiently
activates eosinophils [76].
IL-3, IL-5, and GM-CSF play an important role in adhesion and migration of basophils
and eosinophils across endothelial cells via the upregulation of β2 integrins (CD11/CD18)
expression [74,77–81]. IL-3 was observed to be more potent in upregulating CD11b expres-
sion in basophils than in eosinophils, while IL-5 and GM-CSF were almost equipotent in
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both cell types [79]. In studies using IL-3, IL-5, and GM-CSF cytokines at low concentrations
(150 pg/mL), IL-3 seems to be less efficient than IL-5 or GM-CSF on eosinophils’ migration
across endothelial cells [74]. On the other hand, at higher concentrations of all the three
GM-CSF cytokine members (5 ng/mL), eosinophil migration was equally enhanced [80].
Interestingly, by inhibiting the re-consumption of IL-3 by basophils using a neutralizing
antibody, Schroeder et al. demonstrated that basophils release IL-3 upon cross-linking the
high-affinity IgE receptor [82]. Hence one may speculate that basophils that infiltrated
inflamed tissue attract eosinophils by releasing IL-3 upon allergen binding.
IL-3, IL-5, and GM-CSF effectively prime eosinophils for enhanced chemotactic re-
sponses to various stimuli such as platelet-activating factor, leukotriene B4, and comple-
ment C5a [83]. The most characterized synergism to promote eosinophilia is the interaction
between IL-5 and eotaxin. Studies conducted on eosinophil trafficking in animal mod-
els indicate that IL-5 and eotaxin synergistically regulate eosinophils’ migration during
allergy [84–86].
2.6. Mechanisms of How Basophil Imprint Eosinophil Migration to Inflamed Skin and Lung
Basophils constitute only a minor population infiltrating the tissue compared to
eosinophils. For instance, in IgE-CAI basophil numbers, which were identified as FcεRIpos,
c-Kitneg, accounted for only 2% of infiltrating cells during the chronic phase, in contrast to
eosinophils that accounted for the majority of infiltrating cells, namely 40% [32]. Therefore,
it is justified to ask how such a minority can have such a significant influence. The
study of Cheng et al. gives some more mechanistic insights into basophil and eosinophil
infiltration dependency. In three different-IgE-dependent models of atopic dermatitis,
basophil-derived IL-4 was shown to induce VCAM-1 expression on endothelial cells of
the skin, which resulted in infiltration of eosinophils [8]. Consistently, by using transgenic
basophil-depleted mice, eosinophil infiltration was abrogated. Moreover, by eliminating
IL-4 from basophils, the study demonstrates the non-redundant role of IL-4-producing
basophils in upregulating VCAM-1 on endothelial cells and regulating infiltration of
eosinophils. These findings are consistent with the fact that the interaction between α4β1
integrin, expressed on eosinophils and VCAM-1, displayed by endothelial cells, plays a
significant role in the adhesion of eosinophils to tissue (reviewed in [87]). Thus, basophil-
derived IL-4 might be a possible mechanism for how eosinophil infiltration to inflamed
skin is regulated. Moreover, intranasal injection of soluble IL-4R before OVA-challenge
reduced VCAM-1 expression on endothelial cells of blood vessels in the airways and
blocked eosinophil infiltration [88]. Consistently, in IL-4 deficient mice, fewer eosinophils
were observed in BAL fluid than in wild-type mice [89]. Besides, it is well established
that in synergy with TNF-α, IL-4 promotes the release of CCL11 [90,91], CCL24 [92], and
CCL26 [93] from endothelial cells and fibroblasts. Unfortunately, basophils have not been
addressed in these studies. Notably, however, an increased level of IL-4 concomitantly
with basophils infiltration upon parasite infection was observed, and basophils are known
to be the major source of IL-4 [94–97]. Interestingly, induction of eotaxin-family members
is STAT6 dependent [98,99]. Voehniger et al. observed in lung tissue a non-T non-B
cell population that produce IL-4, which was responsible for eosinophil infiltration and
dependent on STAT6 [96]. One may therefore assume that basophil-derived IL-4 induces
eotaxin-family members in a STAT6-dependent manner, which in turn results in eosinophil
infiltration. A papain-induced airway inflammation model further gives evidence that
basophils indirectly trigger eosinophil infiltration. Namely, basophil-derived IL-4 activated
lung-resident group 2 innate lymphoid cells (ILC2s) to release IL-5, IL-13, and CCL11,
which stimulate infiltration of eosinophils [26].
Besides IL-4, basophils are known to produce IL-13 upon FcεRI cross-linking [100,101].
Pope and their research team demonstrate that intratracheal injection of IL-13 into CCL24-
deficient mice resulted in reduced numbers of eosinophils in BAL fluid. Interestingly,
macrophages in the airway lumen seemed to be the major source of CCL24 [63]. It is
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therefore quite reasonable to speculate that basophil-derived IL-13 stimulates airway
macrophages to release CCL24, which regulates eosinophil recruitment to the airways.
Further, in vitro studies revealed that basophils regulate eosinophils’ infiltration in
co-operation with fibroblast, whereby basophil-derived TNF-α and IL-4 seem to stimulate
CCL11 expression in fibroblast, which in turn attract eosinophils through CCR3. Further-
more, IL-3 induces high expression of CCL5 in basophils, which is further enhanced by
co-culturing of basophils with fibroblast and basophil-derived TNF-α [7]. It is, therefore,
likely that fibroblast-derived CCL11 and IL-3-mediated induction of CCL5 regulate the traf-
ficking of eosinophils [102]. The importance of IL-3 in regulating attraction of eosinophils
to airways is further given by the fact that IL-3 is a very potent inducer of IL-4 and IL-13
from human basophils [76,103,104]. Interestingly, basophil-derived IL-4 and IL-13 can be
inhibited by a blocking anti-IL-3Rα antibody [76] and INF-α treatment [104]. Hence, it
would be interesting to investigate whether, under such treatments, eosinophil infiltration
can be blocked. Moreover, IL-1β induces in synergy with IL-3 the release of IL-8 (own
observation [9]), which was shown to cause eosinophil chemotaxis [105] and thus provides
another mechanism basophil regulate recruitment of eosinophils.
Besides cytokines and chemokines, basophil specific proteases contribute to the re-
cruitment of eosinophils to inflamed tissues. Namely, mouse mast cell proteases (mMCP)-8,
which is expressed explicitly in mouse basophils, triggers leukocyte infiltration by upreg-
ulating the expression of CCL24 (reviewed in [106]). Interestingly, mMCP-8 is highly ho-
mologous to human Granzyme B, which is released upon activating IL-3-primed basophils
with various agonists (anti-FcεRIα, C5a, fMLP) [107]. Whether Granzyme B contributes
to eosinophils chemotaxis in humans has, however, not yet been addressed. In addition,
mMCP-11, a protease preferentially expressed in basophils, seems to attract eosinophils
indirectly by proteolytic cleavage of a yet unidentified serum protein, whose product
triggers recruitment of eosinophils. Consistently, mMCP-11-deficient mice show a dimin-
ished IgE-CIA. Curiously, however, mMCP-11-deficient basophils produce IL-4 in a normal
range upon MCP-2 stimulation (reviewed in [106]), indicating that other mechanisms than
IL-4-dependent induction of VCAM-1 contribute to eosinophil infiltration.
3. Cell-to-Cell Interaction at Sites of Inflammation
Another obvious mechanism, besides chemotaxis, in which cells of different origins
may influence each other is the cell-to-cell contact. A recent book chapter by Landolina et al.
summarizes the interaction of mast cells and eosinophils. The authors describe the forma-
tion of an allergic effector unit (AEU), enabling an enhanced function of both cell types [108].
In addition, studies have demonstrated that basophils and fibroblasts/endothelial cells
directly interact. For instance, direct intercellular contact between basophils and fibrob-
lasts was needed to mediate basophil-derived IL-8, CCL2, and CCL5 secretion upon
NOD2/TLR2 stimulation [109]. Moreover, FcεRI and integrin signaling resulted in cluster-
ing of basophils at endothelial junctions upon allergen challenge in IgE-DNP sensitized
mice. This arrest allowed the local increase of basophil-derived IL-4, which activates IL-4
receptor-expressing endothelial cells to upregulate VCAM-1 [8]. Consistently, the work of
Schroeder and colleagues suggests that cell-to-cell interaction between basophil and lung
epithelial cells triggers histamine, IL-4, and IL-13 release from basophils [110]. Moreover,
studies on whether basophils may act [10,12,111,112] or not [113] as antigen-presenting
cells (APC) stimulated the interest in investigating whether and if so, how basophils in-
teract with T cells and dendritic cells via cell-to-cell contact. For instance, by using YEP
fluorescence expressing basophils and OVA-specific T cells that expressed the red fluo-
rescence protein DsRed, Sullivan and co-workers demonstrated that basophils interact
with T cells in lung tissue but not in lymph nodes upon an N. brasiliensis infection [114].
These findings challenged, on one side, the role of basophils as APC in lymph nodes, but
underscore that basophils interact with T cells by direct cell-to-cell contact resulting in
worsening of Th2 inflammation [115]. Several studies published a few years later further
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investigated the interaction between basophils and different subpopulations of T cells in
variable inflammatory conditions in more detail (reviewed in [116]).
Unfortunately, however, whether basophils and eosinophils have direct cell-to-cell
interaction during allergic inflammation is poorly defined. Nevertheless, the simultaneous
presence of basophils and eosinophils at sites of inflamed skin was observed in chronic aller-
gic dermatitis (ICD) patients giving evidence of basophil and eosinophil couple formation
in vivo. Additionally, the same study confirmed the vicinity of basophils and eosinophils at
inflammatory foci in an IgE-CAI mouse model [33]. Consistently, basophils promote activa-
tion of eosinophils by direct cell interaction, which induces activation markers (CD69, CD86,
and intercellular adhesion molecule-1) on eosinophils [7]. Recently, basophils, eosinophils,
and T cells have been found to co-localize in lung tissue of COPD patients [117]. These few
studies imply that eosinophils and basophils co-localize in inflamed tissue and may affect
each other’s function by cell-to-cell contact. However, currently, the volume of research
on that topic is small, not allowing sound conclusions. Moreover, direct evidence that
basophil and eosinophils form a network of soluble mediators and the corresponding
receptors are mainly missing, too. It is reasonable to speculate that a soluble mediator–
receptor network exists between these two types of granulocytes simply because both
eosinophils and basophils produce and release a plethora of cytokines, chemokines, and
growth factors [13,118], as stated elsewhere [27].
4. Common Molecular Targets on Basophils and Eosinophils for Novel Therapies in
Allergic Inflammation
The simultaneous presence of both basophils and eosinophils has been identified
at the inflammation sites in chronic allergic disorders such as dermatitis, and asthma.
Although they are considerably different in their ability to respond to stimuli, they share
similar characteristics in terms of surface receptors and the inflammatory mediators they
secrete. For instance, both basophils and eosinophils respond to inflammatory stimuli such
as IL-3, IL-5, IL-33, and generate inflammatory cytokines such as IL-4 and IL-13 during
allergic inflammation. Therefore, targeting both basophils and eosinophils together would
be an effective anti-allergic therapeutic strategy. In this section, we summarize the possible
common molecular targets for basophils and eosinophils.
IL-5-IL-5Rα axis: Three monoclonal antibodies targeting the IL-5-IL-5Rα axis have
been developed for clinical purpose. Among them, mepolizumab and reslizumab are hu-
manized mAb that target and neutralize circulating IL-5. Both of them have been approved
for the treatment of adults with severe eosinophilic asthma [119]. Though basophil progen-
itors are unlikely to depend on IL-5 for development, blood basophil counts measured in
routine clinical laboratories suggest they decrease following mepolizumab treatment [120].
However, a recent study by Wright et al. has demonstrated that mepolizumab does not
alter the blood basophil count, and therefore, clinical benefit is likely to be independent
of basophils [121]. Like mepolizumab, reslizumab treatment profoundly decreased cir-
culating eosinophil counts in patients with asthma [122], but its effects on basophils are
not investigated. Benralizumab is directed against the membrane-expressed IL-5Rα-chain
and induces antibody-mediated cellular cytotoxicity (ADCC) in eosinophils, depleting
eosinophils both in blood and tissues [123]. Expression of the IL-5Rα-chain by basophils
makes it a potential target of benralizumab. Laviolette et al. showed that blood basophils
counts were profoundly reduced with benralizumab treatment, but in this study, basophils
have been studied less extensively, and the clinical relevance is unknown [124].
IL-3-IL-3Rα axis: We have previously shown that blocking of the IL-3Rα-chain with
the CSL360, a humanized anti–IL-3Rα mAb, significantly ameliorates the basophil pheno-
type and function [76]. Yet, there are no clinical trials conducted with this mAb. CSL362
is another humanized anti–IL-3RαmAb derived from clone 7G3 that targets and neutral-
izes IL-3. As predicted from in vitro and ex vivo studies, CSL362 produced a marked,
dose-dependent and sustained depletion of peripheral blood basophils and plasmacytoid
dendritic cells (pDCs) [125]. However, there has been no investigation conducted whether
CSL362 affect eosinophil blood counts.
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Anti-alarmins: Airway epithelium is in constant contact with various external stimuli,
such as infectious agents, environmental allergens, and atmospheric pollutants. In response
to such stimuli, airway epithelium releases epithelial-derived cytokines, such as IL-25, IL-33
collectively known as “alarmins”. Among them, IL-33 has been shown to activate both
basophils and eosinophil phenotype, making them attractive targets for biologics [126].
Monoclonal antibodies targeting IL-33 or its receptor, ST2, are in clinical development,
with several in phase 2 trials [127]. Nevertheless, anti-IL-33 and ST2 treatment reduced
airway inflammation in a murine model of asthma and found that both treatments reduced
the total cell counts and eosinophil counts in BAL fluid and significantly reduced the
Th2 cytokine [128]. Recently, Jeannne Allinne et al. conducted a murine study with IL-33
neutralizing antibody REGN3500, which is currently in clinical development to treat asthma
and COPD. Anti-IL-33 neutralizing antibody REGN3500 actively reduced the established
HDM-induced lung infiltration by eosinophils, ST2positive CD4+ T-cell numbers, and Th2
cytokine levels in lungs, and blocks the further increase in lung neutrophilia and levels
of pro-inflammatory cytokines [129]. However, whether anti-IL-33 or anti-ST2 treatment
affects basophils has not been investigated in the above-mentioned studies.
Anti-CCR3: The potential of CCR3 as a therapeutic target was established through
the observations that CCR3-null mice and eotaxin-1 and eotaxin-2 double-knockout mice
displayed significantly reduced allergen-induced airway eosinophil recruitment [130]. A
short-term study was conducted in patients with allergic asthma and control subjects
using a CCR3 antagonist, AXP1275. No significant effect on the number of circulating
eosinophils and sputum eosinophils and metachromatic cells (mast cells and basophils) was
observed [131]. R321 is a novel, biased nanoparticle CCR3 antagonist that inhibits G-protein
signaling but notβ-arrestin-mediated CCR3 internalization and degradation. Intravenously
administered R321 significantly reduces eosinophil recruitment into the blood, lungs,
and airways and prevents airway hyperresponsiveness in a mouse eosinophilic asthma
model [132]. Nevertheless, the effect of R321 on basophils is still unknown.
CRTH2 and PGD2 axis: Chemoattractant receptor-homologous molecule (CRTH2)
is highly expressed on human peripheral blood basophils and eosinophils and has been
shown to mediate chemotaxis of eosinophils and basophils. Prostaglandin D2 (PGD2), one
of the key mediators released by degranulating eosinophils and basophils upon allergen
exposure, is the principal ligand of CRTH2. Royer et al. showed that AZ11665362, a
novel CRTH2 antagonist, is more potent than Ramatroban (BAYu3405, the only clinically
available CRTH2 antagonist) in inhibiting the migration of both human eosinophils and
basophils. Besides, AZ11665362 abrogates the PGD2-induced mobilization of eosinophils
from the bone marrow of the guinea pig [133]. However, more extensive clinical studies
are necessary to understand the clinical relevance of AZ11665362.
Anti-inflammatory cytokines IL-4 and IL-13: Among the recently developed anti-IL-4
and anti-IL-13 biologic drugs, dupilumab is very promising given its ability to inhibit
the biological effects of both IL-4 and IL-13. Dupilumab is a human mAb that is directed
against the shared α-subunit of the IL-4 receptors. It blocked the signaling from IL-4 and
IL-13 and showed efficacy in patients with moderate-to-severe asthma and airway and
peripheral eosinophilia [134]. Dupilumab is the only biologic for asthma treatment that
simultaneously reduces the severe exacerbations but on the other hand transiently increased
blood eosinophilia [135–137]. The increase in the blood eosinophils is consistent with the
hypothesis that duplimuab blocks the migration of eosinophils into tissue by inhibiting
IL-4 and IL-13-mediated production of eotaxin and VCAM-1 expression. Dupilumab
was also approved for treatments in adults with moderate-severe atopic dermatitis [138].
However, the result on eosinophil counts from different clinical studies with dipulimab
treatment in atopic dermatitis is controversial. For instance, no changes in eosinophil count
was observed for dupulimab treatment up to 16 weeks [139]. In contrast, Yamauchi et al.
showed ameliorated blood eosinophilia for up to 32 weeks following dupilumab treatment
in patients with atopic dermatitis [140]. However, the effects of Dipulimab on basophils
has not been investigated.
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Small-molecule inhibitors targeting pro-survival proteins: The therapeutic poten-
tial of directly inhibiting pro-survival proteins was unveiled with the development of
small-molecule inhibitors targeting B cell lymphoma 2 (BCL-2) homology domain 3 (BH3)
mimetics. We have shown that ABT-199, an inhibitor for BCL-2, potently induces apoptosis
in human basophils but not in human eosinophils [141,142]. More importantly, our previ-
ously published studies demonstrated that ABT-263, a selective inhibitor for both BCL-2
and BCL-2-like 1 (BCL-xL), induced cell death of human eosinophils and basophils [141].
However, pre-clinical data predicted a rapid and concentration dependent thrombocytope-
nia as a side effect of ABT-263 [143].
5. Concluding Remarks
We summarized findings on how basophils regulate the infiltration of eosinophils, and
there are a few indications that these two types of granulocytes form cell-to-cell contact in
tissue. The most recent findings demonstrating that basophils mediate eosinophil infiltra-
tion were achieved by mouse and in vitro models [7,8,109] and were published up to seven
years ago. Apparently, there is still a considerable gap of knowledge on this research topic.
Furthermore, studies on possible targets to attenuate and treat allergic inflammation rarely
consider both eosinophils and basophils. This could be due to the technical difficulties in
isolating and phenotyping these minority cells at the inflammatory sites. With the advent of
new approaches like imaging mass cytometry-based studies could help gain more insights
and direct evidence on basophil–eosinophil interactions at inflammatory sites. Considering
that identifying which Th2-endotypes is involved in the pathogenicity of allergy seems
to be a determinant of whether a specific treatment is successful or not [110], we think it
will be essential to study the interaction of basophils and eosinophils in more details in the
future. The simultaneous study of basophils and eosinophils could result in better profiling
of Th2-endotypes, allowing individualized treatment.
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